These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 12907626

  • 1. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
    Abdollahi T, Robertson NM, Abdollahi A, Litwack G.
    Cancer Res; 2003 Aug 01; 63(15):4521-6. PubMed ID: 12907626
    [Abstract] [Full Text] [Related]

  • 2. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 9. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 10. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 11. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 12. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A, Mantovani I, Tazzari PL, Grafone T, Martinelli G, Cocco L, Martelli AM.
    Int J Mol Med; 2005 Dec 15; 16(6):1041-8. PubMed ID: 16273284
    [Abstract] [Full Text] [Related]

  • 13. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 14. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun 01; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 15. Potential for TRAIL as a therapeutic agent in ovarian cancer.
    Abdollahi T.
    Vitam Horm; 2004 Jun 01; 67():347-64. PubMed ID: 15110185
    [Abstract] [Full Text] [Related]

  • 16. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
    Izeradjene K, Douglas L, Delaney AB, Houghton JA.
    Cancer Res; 2004 Nov 01; 64(21):8036-44. PubMed ID: 15520213
    [Abstract] [Full Text] [Related]

  • 17. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 18. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR.
    Biochem Pharmacol; 2006 Jul 28; 72(3):293-307. PubMed ID: 16753135
    [Abstract] [Full Text] [Related]

  • 19. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD.
    Cancer Res; 2002 Jun 01; 62(11):3093-9. PubMed ID: 12036919
    [Abstract] [Full Text] [Related]

  • 20. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I, Marciniak RA.
    Cancer Gene Ther; 2004 Oct 01; 11(10):691-8. PubMed ID: 15354201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.